The mission of the Translational Therapy Shared Resource (TTSR) is to provide state-of-the-art translational research support services to Masonic Cancer Center (MCC) members to facilitate the monitoring of clinical trials and the development of novel GMP-grade cellular and immune-based therapies. These services are essential to the mission of the MCC because transitioning sophisticated laboratory assays and the manufacturing of biotherapeutic products to the clinic can be difficult and often represents a significant hurdle in translating laboratory studies to patient care. TTSR works directly with members of the scientific programs at the preclinical, clinical, and laboratory levels, with the goal of developing clinical trials to test novel therapies. The TTSR is led by Dr. Martin Felices, PhD, and Dr. John Wagner, MD, with support from Drs. Julie Curtsinger, PhD; David McKenna, MD; and their personnel. It has 2 major components, the Translational Therapy Laboratory (TTL) and Molecular and Cellular Therapeutics (MCT). The TTL provides immune monitoring and biorepository management; it is the central laboratory that receives and processes research blood samples from patients enrolled in clinical trials. MCT is a cGMP-compliant production facility capable of generating GMP-grade cellular and molecular products. The 2 components synergize to help translate promising new therapies into the clinic and to assess biologic outcomes once in patients. The resource has undergone the following changes since the 2013 renewal: ? David McKenna was awarded an NHLBI grant to assist with Production Assistance for Cellular Therapies (PACT). This assists with MCT operational funding. ? Our clinical partner, Fairview, increased its investment in TTSR, highlighting their continued commitment to the Resource. This investment is critical for maintaining TTSR personnel and operations going forward. ? The number of TTL-supported studies has gone up 40% since the last CCSG competing renewal application, resulting in an uptick in the number of clinical samples being processed and managed by this component of the core. ? TTL expanded its biorepository capabilities and now supports a number of solid-tumor studies with processing and storage. ? With the departure of Michael Verneris, Martin Felices assumed the role of Co-Director in 2016. Dr. Felices is an Assistant Professor of Medicine who is well versed in basic and translational immunology and has worked extensively with TTL, first as a researcher and later as part of the core leadership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859364
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Kaizer, Alexander M; Hobbs, Brian P; Koopmeiners, Joseph S (2018) A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 74:1082-1094
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 20:1652-1660
Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31
Hwa Yun, Byeong; Guo, Jingshu; Bellamri, Medjda et al. (2018) DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans. Mass Spectrom Rev :
Yun, Byeong Hwa; Bellamri, Medjda; Rosenquist, Thomas A et al. (2018) Method for Biomonitoring DNA Adducts in Exfoliated Urinary Cells by Mass Spectrometry. Anal Chem 90:9943-9950
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplant 53:1069-1071
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933

Showing the most recent 10 out of 1013 publications